Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial
For SHA-HTI children, the success rate and cost for MD-ITI and LD-ITI regimens were similar. MD-ITI regimen would be a priority for regions with economic constraints, considering the shorter time to success, better bleeding control, and no increase in medication cost.
Authors
- Wanru Yao (ORCID: https://orcid.org/0000-0001-7080-3587)
- Man‐Chiu Poon (ORCID: https://orcid.org/0000-0002-7012-2420)
- Liangzhi Xie (ORCID: https://orcid.org/0000-0003-4504-7622)
- Zhenping Chen (ORCID: https://orcid.org/0000-0002-5273-145X)
- Zhengping Li (ORCID: https://orcid.org/0000-0001-6290-9074)
- Yongjun Fang (ORCID: https://orcid.org/0000-0002-1081-6471)
- Jie Huang (ORCID: https://orcid.org/0009-0007-4279-2914)
- Yingzi Zhen
- Heng Zhang (ORCID: https://orcid.org/0000-0001-7091-7496)
- Can Yang
- Zekun Li (ORCID: https://orcid.org/0000-0002-1421-4590)
- Guoqing Liu (ORCID: https://orcid.org/0000-0002-5428-1720)
- Min Zhou (ORCID: https://orcid.org/0000-0003-1770-7822)
- Runhui Wu (ORCID: https://orcid.org/0009-0007-4979-6942)
- Qian Xu
- Xiaoling Cheng
- Jiao Jin
Institutions
- Guiyang Medical University (CN)
- University of Calgary (CA)
- Capital Medical University (CN)
- Chengdu Women's and Children's Central Hospital (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Sinocelltech Group (China) (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1016/j.rpth.2024.102639
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.45
Funders
- National Natural Science Foundation of China
- Beijing Municipal Science and Technology Commission